Minghui Gene Biotechnology

Minghui Gene Biotechnology is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative gene therapies. The company focuses on utilizing Adeno-associated virus (AAV) vectors to treat genetic disorders, with a primary emphasis on ophthalmic and central nervous system (CNS) diseases. Its lead program, MHG-001, is an AAV-based gene therapy targeting RPE65-mediated inherited retinal dystrophies, such as Leber congenital amaurosis. Minghui Gene aims to provide one-time curative treatments for patients with high unmet medical needs through its proprietary vector design and manufacturing capabilities. The company's platform integrates vector optimization, process development, and clinical translation to accelerate the delivery of genetic medicines. Supported by prominent venture capital firms, Minghui Gene is advancing multiple candidates through pre-clinical and clinical development.